Mesothelioma: Bridging the Gap between Preclinical Science and Therapies

Dear Colleagues,

Malignant mesothelioma (MMe) is a cancer with poor prognosis and no effective treatment. Moreover, although restrictive rules that ban or strictly regulate the use of asbestos are in force in many countries, the incidence of this neoplasm has not significantly changed during the last few years but, on the contrary, has begun affecting subjects with no occupational exposure to asbestos and/or genetic susceptibility.

We believe that only a more in-depth insight of the genetic, biological, and immunological mechanisms underlying MMe carcinogenesis and progression will allow providing clinicians with new therapeutic ammunition to improve the prognosis of the patients with MMe.

Some steps forward have been taken in this direction, but there is still a long way to go.

Likewise, what happened in research for other tumors, an interdisciplinary approach to MMe could be the key to achieving our goal to find novel bespoke treatments for this cancer.

Therefore, this Special Issue of Biomedicines aims at providing an exhaustive comprehensive scenario of the new perspective that preclinical research is to offer to the patients in the near future. Original articles or comprehensive reviews on basic and preclinical research are all welcome here, including on the following topics:

• Genetics of MMe;
• Molecular biology and metabolism of MMe;
• Immunology and tumour microenvironment cross talk;
• Novel actionable targets and small molecules.

Prof. Antonio Giordano
Prof. Luciano Mutti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

The Italian Mesothelioma Group (G.I.Me.), a non-profit association that brings together basic and clinical researchers engaged in the research and treatment of this neoplasm, wants to respond, with the creation of this site, to the need to provide patients and even health professionals, the basic information regarding the nature of this tumor, the therapeutic possibilities currently available, and the experimental studies in progress. It also aims to facilitate contacts between patients and their relatives and the international scientific community engaged against this disease

In collaboration with G.I.Me., 10%−20% discount (10% for comprehensive review, while 20% for original article) will be applied to submissions in the Special Issue “Mesothelioma” for the G.I.Me. board members. Please note that if your institute is participating in the MDPI Institutional Open Access Program (IOAP), only one discount from the two alternatives can be applied.

• genetics
• immune response
• microenvironment
• novel actionable targets
• small molecules